Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Woo

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
International Journal of Obesity (2005)|July 2, 2013
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized studyT A Wadden, P Hollander, S Klein, et al.
Deutsche Medizinische Wochenschrift (1946)|March 27, 2013
[Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin]J P H Wilding, V Woo, N G Soler, et al.
Bioconjugate Chemistry|September 1, 1990
Misonidazole conjugates of the colorectal tumor associated monoclonal antibody 17-1AD L Pierce, N D Heindel, K J Schray, et al.
American Journal of Clinical Oncology|June 1, 1988
Monoclonal antibodies for use in radiotherapy and diagnosisD V Woo, A M Markoe, L W Brady, et al.
Journal of Neurosurgical Sciences|July 1, 1990
Iodine125 labeled anti-epidermal growth factor receptor-425 in the treatment of malignant astrocytomas. A pilot studyL W Brady, A M Markoe, D V Woo, et al.
Diabetes, Obesity & Metabolism|September 8, 2015
Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetesH W Rodbard, J B Buse, V Woo, et al.
American Journal of Clinical Oncology|August 1, 1992
Radiotoxicity of 125I-labeled monoclonal antibody 425 against cancer cells containing epidermal growth factor receptorL Derui, D V Woo, J Emrich, et al.
Diabetes & Metabolism|January 8, 2019
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trialsV R Aroda, A Ahmann, B Cariou, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trialL W Brady, C Miyamoto, D V Woo, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|April 26, 2008
The effect of the availability of inhaled insulin on glycaemic control in patients with Type 2 diabetes failing on oral therapy: the evaluation of Exubera as a therapeutic option on insulin initiation and improvement in glycaemic control in clinical practice (EXPERIENCE) trialS Del Prato, L Blonde, L Martinez, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
International Journal of Obesity (2005)|July 2, 2013
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized studyT A Wadden, P Hollander, S Klein, et al.
Deutsche Medizinische Wochenschrift (1946)|March 27, 2013
[Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin]J P H Wilding, V Woo, N G Soler, et al.
Bioconjugate Chemistry|September 1, 1990
Misonidazole conjugates of the colorectal tumor associated monoclonal antibody 17-1AD L Pierce, N D Heindel, K J Schray, et al.
American Journal of Clinical Oncology|June 1, 1988
Monoclonal antibodies for use in radiotherapy and diagnosisD V Woo, A M Markoe, L W Brady, et al.
Journal of Neurosurgical Sciences|July 1, 1990
Iodine125 labeled anti-epidermal growth factor receptor-425 in the treatment of malignant astrocytomas. A pilot studyL W Brady, A M Markoe, D V Woo, et al.
Diabetes, Obesity & Metabolism|September 8, 2015
Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetesH W Rodbard, J B Buse, V Woo, et al.
American Journal of Clinical Oncology|August 1, 1992
Radiotoxicity of 125I-labeled monoclonal antibody 425 against cancer cells containing epidermal growth factor receptorL Derui, D V Woo, J Emrich, et al.
Diabetes & Metabolism|January 8, 2019
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trialsV R Aroda, A Ahmann, B Cariou, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trialL W Brady, C Miyamoto, D V Woo, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|April 26, 2008
The effect of the availability of inhaled insulin on glycaemic control in patients with Type 2 diabetes failing on oral therapy: the evaluation of Exubera as a therapeutic option on insulin initiation and improvement in glycaemic control in clinical practice (EXPERIENCE) trialS Del Prato, L Blonde, L Martinez, et al.
Pageof 5